Show simple item record

dc.contributor.authorTan, Wan C
dc.contributor.authorVollmer, William M
dc.contributor.authorLamprecht, Bernd
dc.contributor.authorMannino, David M
dc.contributor.authorJithoo, Anamika
dc.contributor.authorNizankowska-Mogilnicka, Ewa
dc.contributor.authorMejza, Filip
dc.contributor.authorGislason, Thorarinn
dc.contributor.authorBurney, Peter G J
dc.contributor.authorBuist, A Sonia
dc.date.accessioned2013-09-19T13:59:09Z
dc.date.available2013-09-19T13:59:09Z
dc.date.issued2012-08
dc.date.submitted2013-09-19
dc.identifier.citationThorax 2012, 67(8):718-26en_GB
dc.identifier.issn1468-3296
dc.identifier.pmid22544896
dc.identifier.doi10.1136/thoraxjnl-2011-201445
dc.identifier.urihttp://hdl.handle.net/2336/301893
dc.descriptionTo access publisher's full text version of this article. Please click on the hyperlink in Additional Links field.en_GB
dc.description.abstractCriteria for a clinically significant bronchodilator response (BDR) are mainly based on studies in patients with obstructive lung diseases. Little is known about the BDR in healthy general populations, and even less about the worldwide patterns. 10 360 adults aged 40 years and older from 14 countries in North America, Europe, Africa and Asia participated in the Burden of Obstructive Lung Disease study. Spirometry was used before and after an inhaled bronchodilator to determine the distribution of the BDR in population-based samples of healthy non-smokers and individuals with airflow obstruction. In 3922 healthy never smokers, the weighted pooled estimate of the 95th percentiles (95% CI) for bronchodilator response were 284 ml (263 to 305) absolute change in forced expiratory volume in 1 s from baseline (ΔFEV(1)); 12.0% (11.2% to 12.8%) change relative to initial value (%ΔFEV(1i)); and 10.0% (9.5% to 10.5%) change relative to predicted value (%ΔFEV(1p)). The corresponding mean changes in forced vital capacity (FVC) were 322 ml (271 to 373) absolute change from baseline (ΔFVC); 10.5% (8.9% to 12.0%) change relative to initial value (ΔFVC(i)); and 9.2% (7.9% to 10.5%) change relative to predicted value (ΔFVC(p)). The proportion who exceeded the above threshold values in the subgroup with spirometrically defined Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 2 and higher (FEV(1)/FVC <0.7 and FEV(1)% predicted <80%) were 11.1%, 30.8% and 12.9% respectively for the FEV(1)-based thresholds and 22.6%, 28.6% and 22.1% respectively for the FVC-based thresholds. The results provide reference values for bronchodilator responses worldwide that confirm guideline estimates for a clinically significant level of BDR in bronchodilator testing.
dc.description.sponsorshipALTANA Aventis AstraZeneca Boehringer-Ingelheim Chiesi GlaxoSmithKline Merck Novartis Pfizer Schering-Plough Sepracor University of Kentucky Boehringer Ingelheim Schering Ploughen_GB
dc.language.isoenen
dc.publisherBMJ Pub. Groupen_GB
dc.relation.urlhttp://dx.doi.org/10.1136/thoraxjnl-2011-201445en_GB
dc.relation.urlhttp://thorax.bmj.com/content/67/8/718.full.pdf+htmlen_GB
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3402754/en_GB
dc.rightsArchived with thanks to Thoraxen_GB
dc.subject.meshAdulten_GB
dc.subject.meshAgeden_GB
dc.subject.meshBronchodilator Agentsen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshForced Expiratory Volumeen_GB
dc.subject.meshHumansen_GB
dc.subject.meshMaleen_GB
dc.subject.meshMiddle Ageden_GB
dc.subject.meshPractice Guidelines as Topicen_GB
dc.subject.meshPulmonary Disease, Chronic Obstructiveen_GB
dc.subject.meshReference Valuesen_GB
dc.subject.meshSeverity of Illness Indexen_GB
dc.subject.meshSpirometryen_GB
dc.subject.meshVital Capacityen_GB
dc.subject.meshWorld Healthen_GB
dc.titleWorldwide patterns of bronchodilator responsiveness: results from the Burden of Obstructive Lung Disease study.en
dc.typeArticleen
dc.contributor.departmentUniversity of British Columbia, UBC iCapture Centre for CardioPulmonary Research, St Paul's Hospital, 1081 Burrard Street, Vancouver, BC, Canadaen_GB
dc.identifier.journalThoraxen_GB
dc.rights.accessOpen Access - Opinn aðganguren
html.description.abstractCriteria for a clinically significant bronchodilator response (BDR) are mainly based on studies in patients with obstructive lung diseases. Little is known about the BDR in healthy general populations, and even less about the worldwide patterns. 10 360 adults aged 40 years and older from 14 countries in North America, Europe, Africa and Asia participated in the Burden of Obstructive Lung Disease study. Spirometry was used before and after an inhaled bronchodilator to determine the distribution of the BDR in population-based samples of healthy non-smokers and individuals with airflow obstruction. In 3922 healthy never smokers, the weighted pooled estimate of the 95th percentiles (95% CI) for bronchodilator response were 284 ml (263 to 305) absolute change in forced expiratory volume in 1 s from baseline (ΔFEV(1)); 12.0% (11.2% to 12.8%) change relative to initial value (%ΔFEV(1i)); and 10.0% (9.5% to 10.5%) change relative to predicted value (%ΔFEV(1p)). The corresponding mean changes in forced vital capacity (FVC) were 322 ml (271 to 373) absolute change from baseline (ΔFVC); 10.5% (8.9% to 12.0%) change relative to initial value (ΔFVC(i)); and 9.2% (7.9% to 10.5%) change relative to predicted value (ΔFVC(p)). The proportion who exceeded the above threshold values in the subgroup with spirometrically defined Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 2 and higher (FEV(1)/FVC <0.7 and FEV(1)% predicted <80%) were 11.1%, 30.8% and 12.9% respectively for the FEV(1)-based thresholds and 22.6%, 28.6% and 22.1% respectively for the FVC-based thresholds. The results provide reference values for bronchodilator responses worldwide that confirm guideline estimates for a clinically significant level of BDR in bronchodilator testing.


This item appears in the following Collection(s)

Show simple item record